# Pfizer Raises 2026 Outlook as Eliquis and Cancer Drugs Lift Sales — Patent Risks Remain

- Link: https://tectonicsmediapublications.com/pfizer-raises-2026-outlook-as-eliquis-and-cancer-drugs-lift-sales-patent-risks-remain/
- Published: 2026-11-03T17:01:02+00:00
- Author: News Team

**November 3, 2026.** Pfizer has raised its full-year revenue and adjusted earnings
forecasts after reporting stronger-than-expected third-quarter results, according
to Reuters. The revised outlook is a sign that demand for several established and
acquired medicines is helping offset pressure from fading COVID-19 product sales
and approaching patent expirations.

## What the numbers show

Reuters reported quarterly revenue of $16.58 billion and adjusted earnings of $0.87
per share, ahead of analyst expectations of $15.87 billion and $0.73 respectively.
Pfizer now projects 2026 revenue of $62 billion to $64 billion and adjusted earnings
of $2.95 to $3.05 per share. These are company forecasts, not achieved full-year
results.

Sales of the anticoagulant Eliquis reportedly increased 25% to $2.52 billion. Cancer
medicine Padcev also contributed to demand. The performance highlights the importance
of the company’s non-COVID portfolio, although individual product growth should 
not be confused with company-wide growth.

## Why it matters

Investors will watch whether growth from oncology and other medicines can persist
as older products lose exclusivity. Acquisitions and research programmes could create
new sources of revenue, but clinical outcomes, regulatory approvals and integration
costs remain uncertain. A stronger annual forecast does not eliminate those risks.

**Source verification and image credit:** Pfizer’s November 3 earnings figures were
checked against its official release and independent reporting. Illustrative laboratory
image: Nathan Rimoux / Unsplash; it does not depict Pfizer facilities or products.

## Sources

[Reuters, November 3, 2026: Pfizer raises forecast](https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-raises-2026-forecast-strong-demand-blood-thinner-eliquis-2026-11-03/);
[Pfizer Investor Relations: third-quarter 2026 webcast and materials](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-strong-third-quarter-2026-results-and-raises).

Please follow and like us:

[[

[ ⌊fb-share-icon⌉](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Ftectonicsmediapublications.com%2Fpfizer-raises-2026-outlook-as-eliquis-and-cancer-drugs-lift-sales-patent-risks-remain%2F)

[ ⌊Tweet⌉ ](https://x.com/intent/post?text=Pfizer+Raises+2026+Outlook+as+Eliquis+and+Cancer+Drugs+Lift+Sales+%E2%80%94+Patent+Risks+Remain%20https%3A%2F%2Ftectonicsmediapublications.com%2Fpfizer-raises-2026-outlook-as-eliquis-and-cancer-drugs-lift-sales-patent-risks-remain%2F)

[⌊Pin Share⌉⌊Pin Share⌉[

 Share via:

 *  [   Facebook  ](https://tectonicsmediapublications.com/pfizer-raises-2026-outlook-as-eliquis-and-cancer-drugs-lift-sales-patent-risks-remain/#)
 *  [   X (Twitter)  ](https://tectonicsmediapublications.com/pfizer-raises-2026-outlook-as-eliquis-and-cancer-drugs-lift-sales-patent-risks-remain/#)
 *  [   LinkedIn  ](https://tectonicsmediapublications.com/pfizer-raises-2026-outlook-as-eliquis-and-cancer-drugs-lift-sales-patent-risks-remain/#)
 *  [    More   ](https://tectonicsmediapublications.com/pfizer-raises-2026-outlook-as-eliquis-and-cancer-drugs-lift-sales-patent-risks-remain/#)